News of the FDA approving the lung drug from Discovery Laboratories, Inc. (NASDAQ: DSCO) may be a game changing event. The company’ Surfaxin for lung development in premature births has tried to get approved four times before, and the fifth was the charm. Shares are up over 20% at $4.52 on more than 20 million shares. There are a couple of things to consider here besides just recapping the news.
For starters, Discovery had a lot riding on this. Even though there is competition, four attempts to get approval is costly by any count.
The company has a market capitalization rate of only about $110 million, and some have signaled that this could have the potential of being a blockbuster drug if the best case scenarios play out.
Discovery Laboratories probably needs to raise capital, and a 20% gain to $4.50 probably makes that easier on the heels of an FDA approval.
The company plans a late-2012 launch for the drug, on its own here and it is looking for international partners. The approval is also on the heels of its device Afectair being prepared for launch this year after it was approved.
Surfaxin will be the first synthetic surfactant approved for the prevention of respiratory distress syndrome.
The company has two other surfactant trials in its pipeline, both of which are said to be mid-stage.
Shares are up 20% at $4.50 today, but the stock did trade over $5.00 earlier and the prior 52-week trading range was $1.44 to $4.57.
JON C. OGG
ALERT: Today Could Be Your Best Shot At Early Retirement (Sponsored)
If you want to retire before 65, pay attention. Study after study has shown that the longer you stay invested, the better your chances at an early retirement.
Every day that goes by without saving and investing for tomorrow means more to earn and save later. Don’t waste any more time and get started with Robinhood today. The app makes it easy to buy and sell stocks, mutual funds, trade options, and even cryptocurrencies.
Sign up today — click here to start your journey.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.